News >

No Benefit With Prolonged Native E. Coli Asparaginase in Pediatric ALL, NHL

Jason Harris
Published: Wednesday, Oct 25, 2017

Treatment with prolonged native E. coli asparaginase therapy for children with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) not only failed to improve survival versus the standard regimen, but also resulted in an increase in infections and allergy.

A total of 641 patients in the long-course group and 750 in the short-course arm received the per-protocol number of treatments. In the long-course group, 103 patients (13.3%) received an incomplete number of administrations and/or insufficient dose of E. coli asparaginase. Thirteen patients (1.7%) in the short-course arm were undertreated.
Mondelaers V, Suciu S, De Moerloose B, et al. Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017;102(10):1727-1738. doi: 10.3324/haematol.2017.165845.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Publication Bottom Border
Border Publication